# US 2024/0174659 A1 · Compounds and methods for yap/tead modulation and indications therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174659 A1
- Document ID: US20240174659A1
- Status: Published application
- Kind: A1
- Application number: 18/505,538
- Filed: 2023-11-09
- Published: 2024-05-30
- Earliest claimed: 2021-05-11
- Assignees: Opna Bio SA
- Applicants: Opna Bio SA
- Inventors: Aaron Albers; Zuojun Guo; Cuong Ly; Wayne Spevak; Mark Vander Wal; Dongyu Zhang; Jiazhong Zhang; Ying Zhang
- Web page: https://patentgrep.com/patent/US20240174659A1

## CPC

- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- B60L 53/302: Cooling of charging equipment
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- B60L 53/18: Cables specially adapted for charging electric vehicles
- C07D 217/06: with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 217/08: with a hetero atom directly attached to the ring nitrogen atom
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- H01B 7/423: {using a cooling fluid}
- Y02T 10/70: Energy storage systems for electromobility, e.g. batteries
- Y02T 10/7072: Electromobility specific charging systems or methods for batteries, ultracapacitors, supercapacitors or double-layer capacitors
- Y02T 90/12: Electric charging stations
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B60L: PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES (arrangements or mounting of electrical propulsion units or of plural diverse prime-movers for mutual or common propulsion in vehicles B60K1/00, B60K6/20; arrangements or mounting of electrical gearing in vehicles B60K17/12, B60K17/14; preventing wheel slip by reducing power in rail vehicles B61C15/08; dynamo-electric machines H02K; control or regulation of electric motors H02P); SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES (electric coupling devices combined with mechanical couplings of vehicles B60D1/64; electric heating for vehicles B60H1/00); ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL (control or regulation of electric motors H02P); MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- H01B: CABLES; CONDUCTORS; INSULATORS; SELECTION OF MATERIALS FOR THEIR CONDUCTIVE, INSULATING OR DIELECTRIC PROPERTIES (selection for magnetic properties H01F1/00; waveguides H01P {; printed circuits H05K})
- Y02T: CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION

## Abstract

Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, R3, R4, L and X are as described in any of the embodiments described in this disclosure; compositions thereof, and uses thereof.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:
R1 is phenyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein R1 is substituted with 0-1 G1 groups and 0-4 G2 groups;
X is —C(O)— or —S(O)2—;
G1 is —S(O)2 alkyl, cycloalkyl optionally substituted with one or more R5, or phenyl optionally substituted with one or more R5;
each G2 is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R5, alkoxy optionally substituted with one or more R5;
each R2 is independently H, halogen, —C(O)O-alkyl or C1-C3 alkyl optionally substituted with 1-3 halogens or two R2 groups together with the carbon to which they are attached can form —CO— provided that not more than one R2 is —C(O)O-alkyl;
L is —O—, —OC(R8)2—, —N(R6)—, —N(R6)—C(R8)2, —[C(R8)2]1-2—, —C(R8)2O—, or —C(R8)2—N(R6)—;
R3 is H, halogen, alkyl, hydroxyalkyl, or haloalkyl;
R4 is H, halogen, alkyl, hydroxyalkyl, heterocycloalkylalkyl, heteroarylalkyl, or -alkyl-N(R6)2, wherein each alkyl, hydroxyalkyl, heterocycloalkylalkyl, heteroarylalkyl, -alkyl-N(R6)2 is optionally substituted with 1-3 R7;
each R5 is independently halogen or OH;
each R6 is independently H or alkyl optionally substituted with one or more R5;
each R7 is independently alkyl, alkoxy, hydroxyalkyl, halogen, or hydroxy; and
each R8 is independently H, halogen, or alkyl optionally substituted with one or more R5.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
R1 is phenyl, 5-6 membered heteroaryl, C4-C10 cycloalkyl, or 5-6 membered heterocycloalkyl,
wherein R1 is substituted 0-4 G2 groups,
each G2 is independently selected from halogen, OH, CN, C1-C6 alkyl optionally substituted with 1-3 R5, C1-C6alkoxy optionally substituted with 1-3 R5;
each R2 is independently H, halogen, or CH3;
R3 is H, halogen C1-C3 alkyl, C1-C3hydroxyalkyl, or C1-C3haloalkyl;
L is —O—, —OCH2—, —N(H)—, —N(CH3)—, —N(H)—C(R8)2, —[(CR8)2]1-2—, —C(R8)2O—, or —C(R8)2—N(H);
R4 is H, halogen, C1-C6 alkyl, C1-C6hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or —C1-C6 alkyl-N(R6)2, wherein each C1-C6 alkyl, C1-C6hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or -alkyl-N(R6)2 is optionally substituted with 1-3 R7;
each R5 is independently halogen C1-C3haloalkyl, or OH;
each R6 is independently H or C1-C6 alkyl optionally substituted with 1-3 R5;
each R7 is independently C1-C6 alkyl, C1-C6alkoxy, C1-C6hydroxyalkyl, halogen, or hydroxy; and
each R8 is independently H, halogen, or C1-C6 alkyl optionally substituted with 1-3 R5.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein:
R1 is phenyl, 5-6 membered heteroaryl, C4-C10 cycloalkyl, or 5-6 membered heterocycloalkyl, wherein R1 is substituted 0-3 G2 groups,
each G2 is independently selected from Cl, F, OH, CN, C1-C4 alkyl optionally substituted with 1-3 R5, C1-C4alkoxy optionally substituted with 1-3 R5;
each R2 is independently H, Cl, F, or CH3;
R3 is H, Cl, F, C1-C2 alkyl, C1-C2hydroxyalkyl, or C1-C2haloalkyl;
L is —O—, —OCH2—, —N(H)—, or N(H)C(H)2;
R4 is H, F, Cl, C1-C4 alkyl, C1-C4hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or —C1-C4 alkyl-N(R6)2, wherein each C1-C4 alkyl, C1-C4hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or—C1-C4 alkyl-N(R6)2 is optionally substituted with 1-3 R7;
each R5 is independently Cl, F, or OH;
each R6 is independently H or C1-C4 alkyl optionally substituted with 1-3 R5;
each R7 is independently C1-C4 alkyl, C1-C4alkoxy, C1-C4hydroxyalkyl, Cl, F, or hydroxy; and
each R8 is independently H, halogen or C1-C4 alkyl optionally substituted with 1-3 R5.

### Claim 4 (depends on 1)

A compound according to claim 1 having one of the following formulae:
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae IIa, IIb, IIc, IId or IIe.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein:
R1 is phenyl, 5-6 membered heteroaryl, C4-C10 cycloalkyl, or 5-6 membered heterocycloalkyl, wherein R1 is substituted 0-4 G2 groups,
each G2 is independently selected from halogen, OH, CN, C1-C6 alkyl optionally substituted with one or more R5, C1-C6alkoxy optionally substituted with 1-3 R5;
R2 is H, halogen, or CH3;
R4 is H, halogen, C1-C6 alkyl, C1-C6hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or —C1-C6 alkyl-N(R6)2, wherein each C1-C6 alkyl, C1-C6hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or -alkyl-N(R6)2 is optionally substituted with 1-3 R7;
each R5 is independently halogen C1-C3haloalkyl, or OH;
each R6 is independently H or C1-C6 alkyl optionally substituted with 1-3 R5;
each R7 is independently C1-C6 alkyl, C1-C6alkoxy, C1-C6hydroxyalkyl, halogen, or hydroxy; and
each R8 is independently H, halogen, or C1-C6 alkyl optionally substituted with 1-3 R5.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein:
R1 is phenyl, 5-6 membered heteroaryl, C4-C10 cycloalkyl, or 5-6 membered heterocycloalkyl, wherein R1 is substituted 0-3 G2 groups,
each G2 is independently selected from Cl, F, OH, CN, C1-C4 alkyl optionally substituted with one or more R5, C1-C4alkoxy optionally substituted with 1-3 R5;
R2 is H, Cl, F, or CH3;
R4 is H, F, Cl, C1-C4 alkyl, C1-C4hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or —C1-C4 alkyl-N(R6)2, wherein each C1-C4 alkyl, C1-C4hydroxyalkyl, 4-6 membered heterocycloalkylalkyl, 5-6 membered heteroarylalkyl, or—C1-C4 alkyl-N(R6)2 is optionally substituted with 1-3 R7;
each R5 is independently Cl, F, or OH;
each R6 is independently H or C1-C4 alkyl optionally substituted with 1-3 R5;
each R7 is independently C1-C4 alkyl, C1-C4alkoxy, C1-C4hydroxyalkyl, Cl, F, or hydroxy; and
each R8 is independently H, halogen, or C1-C4 alkyl optionally substituted with 1-3 R5.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein R1 is phenyl or pyridyl substituted with 1-3 groups independently selected from Cl, F, CF3 and CN.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein R1 is phenyl or pyridyl, wherein the phenyl or pyridyl is substituted with 1 CF3 and optionally substituted with 1-2 F.

### Claim 9 (depends on 1)

A formic acid salt according to the compound according to claim 1.

### Claim 10

A compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, further comprising a second pharmaceutical agent.

### Claim 13 (depends on 1)

A method for treating a subject with a disease or condition mediated by YAP/TEAD, said method comprising administering to the subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof.

### Claim 14 (depends on 13)

A method for treatment of a disease or condition according to claim 13, wherein the disease or condition is a cancer, a neurodegenerative disease, a heart related disorder, or a kidney-related disorder.

### Claim 15 (depends on 13)

A method for treatment of a disease or condition according to claim 13, wherein the disease or condition is polycystic kidney disease, Alzheimer's disease, arrhythmogenic cardiomyopathy, Holt-Oram syndrome, liver cancer, epithelioid hemangioendothelioma, breast cancer, lung cancer, malignant mesothelioma, pancreatic cancer, Kaposi sarcoma, uveal melanoma, renal cell carcinoma, colorectal cancer, multiple myeloma, neurofibromatosis Type 2, glioma, or glioblastoma.

### Claim 16 (depends on 13)

The method according to claim 13, further comprising administering one or more additional therapeutic agents.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the one or more additional therapeutic agents is one or more of i) an alkylating agent selected from adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan; ii) an antibiotic selected from bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin; iii) an antimetabolite selected from azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate; iv) an immune checkpoint agent selected from a PD-1 inhibitor, a PD-L1 inhibitor, and an anti-CTLA4 inhibitor; v) a hormone or hormone antagonist selected from enzalutamide, abiraterone, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene; vi) a taxane selected from DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel; vii) a retinoid selected from alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin; viii) an alkaloid selected from etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine; ix) an antiangiogenic agent selected from AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide; x) a topoisomerase inhibitor selected from amsacrine, edotecarin, exatecan, irinotecan, SN-38 (7-ethyl-10-hydroxy-camptothecin), rubitecan, topotecan, and 9-aminocamptothecin; xi) a kinase inhibitor selected from erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, 7-hydroxystaurosporine, and vatalanib; xii) a targeted signal transduction inhibitor selected from bortezomib, geldanamycin, and rapamycin; xiii) a biological response modifier selected from imiquimod, interferon-α and interleukin-2; xiv) an IDO inhibitor; xv) a chemotherapeutic agent selected from 3-AP (3-amino-2-carboxyaldehyde thiosemicarbazone), altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate, ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, an mTOR inhibitor, a PI3K inhibitor, a Cdk4 inhibitor, an Akt inhibitor, a Hsp90 inhibitor, a farnesyltransferase inhibitor and an aromatase inhibitor (anastrozole letrozole exemestane); xvi) a BRAF inhibitor; xvii) a Mek inhibitor; xviii) c-Kit mutant inhibitor, xix) an EGFR inhibitor, xx) an epigenetic modulator; xxi) other adenosine axis blockade agents selected from CD39, CD38, A2AR and A2BR; or xxii) agonists of TNFA super family member; and xxiii) an anti-ErbB2 mAb.
